孟鲁司特钠联合沙美特罗替卡松治疗慢性阻塞性肺疾病的疗效观察

Observation on Efficacy of Montelukast Sodium Combined with Salmeterol and Fluticasone in Treatment of Chronic Obstructive Pulmonary Disease

目的:探讨孟鲁司特钠联合沙美特罗替卡松治疗慢性阻塞性肺疾病的临床疗效。方法:选取2015年6月—2016年5月河南省唐河县中医院收治的慢性阻塞性肺疾病患者124例作为研究对象,以随机数字表法分为观察组和对照组,每组62例。对照组患者给予沙美特罗替卡松粉吸入剂,观察组患者在对照组的基础上加用孟鲁司特钠片,两组患者均治疗12周。观察两组患者的临床疗效、肺功能指标、呼吸困难评分、日常生活能力评分、随访1年的住院次数及不良反应发生情况。结果:观察组患者的总有效率为96.77%(60/62),明显高于对照组的80.65%(50/62);治疗后,观察组患者FVC、FEV1明显优于对照组,呼吸困难评分明显低于对照组,日常生活能力评分明显高于对照组,上述差异均有统计学意义(P<0.05);随访1年,观察组患者平均复发次数为(0.4±0.2)次,明显低于对照组的(1.1±0.1)次,差异有统计学意义(P<0.05);观察组、对照组患者不良反应发生率分别为3.23%(2/62)、4.84%(3/62),差异无统计学意义(P>0.05)。结论:孟鲁司特钠联合沙美特罗替卡松治疗慢性阻塞性肺疾病的疗效显著,可改善患者肺功能,提高患者生活质量,且不良反应少。

OBJECTIVE： To probe into the clinical efficacy of montelukast sodium combined with salmeterol and fluticasone in treatment of chronic obstructive pulmonary disease（ COPD）. METHODS： 124 patients with COPD admitted into Henan Tanghe County Traditional Chinese Medicine Hospital from Jun. 2015 to May 2016 were extracted to be divided into observation group and control group via the random number table,with 62 cases in each. The control group was given salmeterol and fluticasone propinate for inhalation,while the observation group additionally received montelukast sodium tablets based on the control group; the treatment course was 12 weeks. The clinical efficacy,lung function indices,dyspnea score,daily life ability score,number of admissions and incidence of adverse drug reactions within one year of follow-up of two groups were observed. RESULTS： The total effective rate of observation group was96. 77%（ 60/62）,significantly higher than that of control group [80. 65%（ 50/62） ]. After treatment,the FVC and FEV1 of observation group were better than those of control group,the dyspnea score was significantly lower than the control group,and the daily life ability score was higher than that of control group,with statistically significant differences（ P〈0. 05）. After follow-up of 1 year,the average number of admissions of observation group was（ 0. 4 ±0. 2） times,significantly lower than that of control group（ 1. 1 ± 0. 1） times,with statistically significant difference（ P〈0. 05）. The incidence of adverse drug reactions of two groups were respectively 3. 23%（ 2/62） and 4. 84%（ 3/62）,without any statistically significant differences（ P〉0. 05）. CONCLUSIONS： The efficacy of montelukast sodium combined with salmeterol and fluticasone in treatment of COPD is remarkable,which can improve patients＇ lung function and life quality with few adverse drug reactions.